These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15195775)

  • 1. Rheumatoid arthritis: more aggressive approach improves outlook.
    Weinblatt ME
    Cleve Clin J Med; 2004 May; 71(5):409-13. PubMed ID: 15195775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the medical management of rheumatoid arthritis.
    Scott DL
    Hosp Med; 2002 May; 63(5):294-7. PubMed ID: 12066349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.
    Francis S; Block MJ
    Arthritis Rheum; 2010 Sep; 62(9):2826; author reply 2826-8. PubMed ID: 20556822
    [No Abstract]   [Full Text] [Related]  

  • 4. Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
    Kremer JM
    Ann Intern Med; 2001 Apr; 134(8):695-706. PubMed ID: 11304108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapies for active rheumatoid arthritis after methotrexate failure.
    O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
    N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer approaches to the treatment of rheumatoid arthritis.
    Finesilver AG
    WMJ; 2003; 102(7):34-7. PubMed ID: 14711022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
    Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
    Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in the treatment of rheumatoid arthritis.
    Pisetsky DS; St Clair EW
    JAMA; 2001 Dec; 286(22):2787-90. PubMed ID: 11735734
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [TNF targetting therapy for rheumatoid arthritis].
    Takeuchi T
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1787-94. PubMed ID: 17037316
    [No Abstract]   [Full Text] [Related]  

  • 12. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
    Baker DE
    Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional triple therapy as good as etanercept for uncontrolled rheumatoid arthritis.
    BMJ; 2013 Jun; 346():f3846. PubMed ID: 23778977
    [No Abstract]   [Full Text] [Related]  

  • 14. Making rational treatment decisions in rheumatoid arthritis when methotrexate fails.
    Bathon JM; McMahon DJ
    N Engl J Med; 2013 Jul; 369(4):384-5. PubMed ID: 23755970
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biologic therapy with anti-TNFα in rheumathoid arthritis].
    Ferraccioli G
    Reumatismo; 2005; 57(4 Suppl):17-21. PubMed ID: 16385351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?
    van Vollenhoven RF; Chatzidionysiou K
    Nat Rev Rheumatol; 2013 Sep; 9(9):510-2. PubMed ID: 23897440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.
    Hochberg MC; Tracy JK; Hawkins-Holt M; Flores RH
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii13-6. PubMed ID: 14532140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR; Hay J
    Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
    Jani M; Chinoy H; Warren RB; Griffiths CE; Plant D; Fu B; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Barton A;
    Arthritis Rheumatol; 2015 May; 67(8):2011-9. PubMed ID: 26109489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
    Mora C; González A; Díaz J; Quintana G
    Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.